BRAF inhibitors vemurafenib and dabrafenib have become the standard of care for treatment of stage IV metastatic melanoma harboring a BRAF mutation. Panniculitis is a rare but known adverse side effect of these agents and presents with tender erythematous nodules. These nodules may demonstrate uptake on F-FDG PET/CT, which may mimic metastatic disease in patients undergoing treatment. We present a case of BRAF inhibitor-induced panniculitis in a patient with stage IV metastatic melanoma and discuss the imaging findings on F-FDG PET/CT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0000000000001027 | DOI Listing |
Publication Analysis
Top Keywords
braf inhibitor-induced
8
inhibitor-induced panniculitis
8
stage metastatic
8
metastatic melanoma
8
f-fdg pet/ct
8
braf
4
panniculitis appearance
4
appearance 18f-fdg
4
18f-fdg pet/ct
4
pet/ct braf
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!